142 related articles for article (PubMed ID: 1562744)
1. Are serum interleukin-6 levels always useful for differentiating monoclonal gammopathies in unselected patients?
Greco C; Vitelli G; Cianciulli AM; Alvino S; Gandolfo GM; Ameglio F
Blood; 1992 Apr; 79(8):2173-4. PubMed ID: 1562744
[No Abstract] [Full Text] [Related]
2. Development of a "Myeloma Risk Score" using a population-based registry on paraproteinemia and myeloma.
Ong F; Hermans J; Noordijk EM; De Kieviet W; Seelen PJ; Wijermans PW; Kluin-Nelemans JC
Leuk Lymphoma; 1997 Nov; 27(5-6):495-501. PubMed ID: 9477131
[TBL] [Abstract][Full Text] [Related]
3. Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers.
Greco C; Ameglio F; Alvino S; Cianciulli AM; Giovannelli M; Mattei F; Vitelli G; Venturo I; Lopez M; Gandolfo GM
Acta Haematol; 1994; 92(1):1-7. PubMed ID: 7985475
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD56 (NCAM): a new differential-diagnostic and prognostic marker in multiple myeloma.
Kaiser U; Oldenburg M; Jaques G; Auerbach B; Havemann K
Ann Hematol; 1996 Sep; 73(3):121-6. PubMed ID: 8841099
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of the new Hevylite™ IgA assay for the diagnosis and follow-up of monoclonal gammopathies].
Lakomy D; Lemaire-Ewing S; Denimal D; Bastie JN; Lafon I; Caillot D
Ann Biol Clin (Paris); 2013; 71(2):157-63. PubMed ID: 23587579
[TBL] [Abstract][Full Text] [Related]
6. Bone remodelation markers are useful in the management of monoclonal gammopathies.
Hernández JM; Suquía B; Queizan JA; Fisac RM; Sanchez JJ; Fernández-Calvo FJ; García-Sanz R; Olivier C; Bárez A; Calmuntia MJ; García-Frade J; Portero JA; López R; Aguilera C; Navajo JA; San-Miguel JF
Hematol J; 2004; 5(6):480-8. PubMed ID: 15570289
[TBL] [Abstract][Full Text] [Related]
7. [Diagnostic problems in monoclonal gammopathies].
Tilz GP; Becker H; Lanzer G
Acta Med Austriaca; 1982; 9(4):139-42. PubMed ID: 6814156
[TBL] [Abstract][Full Text] [Related]
8. Analytical performance and diagnostic potential of immunoassays determining intact immunoglobulin kappa/lambda ratios in monoclonal gammopathies.
Eckold J; Poenisch W; Drogies T; Kratzsch J; Teupser D; Thiery J; Bruegel M
Clin Lab; 2014; 60(9):1491-500. PubMed ID: 25291945
[TBL] [Abstract][Full Text] [Related]
9. Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes.
Ong F; Kaiser U; Seelen PJ; Hermans J; Wijermans PW; de Kieviet W; Jaques G; Kluin-Nelemans JC
Blood; 1996 Jan; 87(2):712-6. PubMed ID: 8555495
[TBL] [Abstract][Full Text] [Related]
10. Immunological methods in the diagnosis of monoclonal gammopathies. The prognostic impact of the immunological data.
Baldea L; Cucuianu A; Cristea A
Rom J Intern Med; 1999; 37(3):217-25. PubMed ID: 15532300
[TBL] [Abstract][Full Text] [Related]
11. IgD-λ multiple myeloma with excessive excretion of free light chains: a diagnostic trap in the identification of monoclonal gammopathies.
Zahir H; Tali A; Rachidi M; Mouhib H; Daif H; Ait Ouzdi Z; Haouach K; Chabaa L
Ann Biol Clin (Paris); 2019 Feb; 77(1):107-111. PubMed ID: 30799291
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of serum IL-6 level in monoclonal gammopathies.
DuVillard L; Guiguet M; Casasnovas RO; Caillot D; Monnier-Zeller V; Bernard A; Guy H; Solary E
Br J Haematol; 1995 Feb; 89(2):243-9. PubMed ID: 7873373
[TBL] [Abstract][Full Text] [Related]
13. Immunoreactive interleukin-6 and C-reactive protein in plasma cell disorders.
Smith SR; Morgan L
Br J Haematol; 1994 Aug; 87(4):883-4. PubMed ID: 7986740
[No Abstract] [Full Text] [Related]
14. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias.
Mayo MM; Johns GS
Contrib Nephrol; 2007; 153():44-65. PubMed ID: 17075223
[TBL] [Abstract][Full Text] [Related]
15. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma.
Mathiot C; Teillaud JL; Elmalek M; Mosseri V; Euller-Ziegler L; Daragon A; Grosbois B; Michaux JL; Facon T; Bernard JF
J Clin Immunol; 1993 Jan; 13(1):41-8. PubMed ID: 8445043
[TBL] [Abstract][Full Text] [Related]
16. Benefits of new immunoglobulin-derived biomarkers for the diagnosis and follow-up of patients with dysglobulinemia.
Ermak N; Nguyen-Khoa T; Alyanakian MA
Ann Biol Clin (Paris); 2016 Oct; 74(5):597-605. PubMed ID: 27707674
[TBL] [Abstract][Full Text] [Related]
17. Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.
Milani P; Palladini G; Merlini G
Scand J Clin Lab Invest Suppl; 2016; 245():S113-8. PubMed ID: 27467897
[TBL] [Abstract][Full Text] [Related]
18. Serum beta 2-microglobulin in patients with monoclonal gammopathies.
Di Giovanni S; Valentini G; Ravazzolo E; Carducci P; Giallonardo P; Maschio C
Int J Biol Markers; 1987; 2(3):169-72. PubMed ID: 3131451
[TBL] [Abstract][Full Text] [Related]
19. Impaired production of interleukin 6 and tumour necrosis factor alpha in whole blood cell cultures of patients with multiple myeloma.
Filella X; Bladé J; Montoto S; Molina R; Coca F; Montserrat E; Ballesta AM
Cytokine; 1998 Dec; 10(12):993-6. PubMed ID: 10049525
[TBL] [Abstract][Full Text] [Related]
20. The discriminating analysis in the differential diagnosis of monoclonal gammopathies.
Büchi G; Veglio M; Reviglione G; Grosso E; Termine G; Girotto M; Autino R
Pathologica; 1993; 85(1096):175-81. PubMed ID: 8361780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
